Dr. Johnathan D. Goodwin, M.D.
Gastroenterology (Gastroenterology Physician)
- Medicare participating
At a glance
- Medical school
- University of Texas Southwestern Medical School at Dallas (2009)
- Years since graduation
- 17
- In the NPI registry since
- 2009
- Medicare patients seen, 2024
- 655
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2009Medical school: University of Texas Southwestern Medical School at Dallas
- 2009Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gastroenterology Physician primary
AR license E9623 -
Hospitalist Physician
MO license 2011036079
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Baptist Health Medical Center-Little Rock Little Rock, AR
- Baptist Health Medical Center North Little Rock North Little Rock, AR
Medical groups
- Gastro Clinics of Arkansas PLLC (7 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 655
- Services billed
- 2,534
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Pathology examination of tissue using a microscope, intermediate complexity | 490 | 235 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 181 | 179 |
| Biopsy of large bowel using a flexible endoscope | 167 | 166 |
| Special stained specimen slides to examine tissue including interpretation and report | 166 | 128 |
| Special stained specimen slides to identify organisms including interpretation and report | 142 | 125 |
| Established patient office or other outpatient visit, 20-29 minutes | 127 | 114 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | 111 | 82 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 102 | 102 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 101 | 61 |
| New patient office or other outpatient visit, 30-44 minutes | 99 | 99 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Pantoprazole Sodium Other prescribers in North Little Rock, AR | 718 |
| Omeprazole Other prescribers in North Little Rock, AR | 509 |
| Colestipol Hcl Other prescribers in North Little Rock, AR | 155 |
| Peg-3350 And Electrolytes (peg3350/sod sulf,bicarb,cl/kcl) Other prescribers in North Little Rock, AR | 148 |
| Gavilyte-G (peg3350/sod sulf,bicarb,cl/kcl) Other prescribers in North Little Rock, AR | 130 |
| Famotidine Other prescribers in North Little Rock, AR | 103 |
| Dicyclomine Hcl Other prescribers in North Little Rock, AR | 75 |
| Sucralfate Other prescribers in North Little Rock, AR | 70 |
| Linzess (linaclotide) Other prescribers in North Little Rock, AR | 69 |
| Esomeprazole Magnesium Other prescribers in North Little Rock, AR | 59 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 12 companies reported 49 payments worth $763 in total to this clinician.
| AbbVie Inc. | $340 |
|---|---|
| Janssen Biotech, Inc. | $78.80 |
| Regeneron Healthcare Solutions, Inc. | $57.81 |
| Genzyme Corporation | $50.61 |
| Medtronic, Inc. | $45.77 |
| Aimmune Therapeutics, Inc. | $44.23 |
| Takeda Pharmaceuticals U.S.A., Inc. | $34.35 |
| Evoke Pharma, Inc. | $33.58 |
| Food and Beverage | $763 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $183,163 in research payments for these studies, mostly to the institutions running them.
- 17 b-hydroxysteroid dehydrogenase type 13 minimization for the treatme
GlaxoSmithKline, LLC. - A 26-Wk Study to Assess Safety & Efficacy of Tenapanor for T/t of Chronic Idiopathic Constipation in Adults
Ardelyx, Inc. · Recruiting · NCT07382167
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.